{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=19",
    "query": {
      "intervention": "0.9 % sodium chloride",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 2426,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:06:52.009Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05335993",
      "title": "A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Recurrent Epithelial Cancer of Ovary",
        "Recurrent Epithelial Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Recurrent Carcinoma of Ovary",
        "Adenocarcinoma of Ovary"
      ],
      "interventions": [
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CanariaBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2022-07-25",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05335993"
    },
    {
      "nct_id": "NCT00660036",
      "title": "Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Gemtuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-09",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2016-01-15",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00660036"
    },
    {
      "nct_id": "NCT04221828",
      "title": "Trial of NanoPac Focal Therapy for Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Adenocarcinoma",
        "Prostate Cancer Adenocarcinoma",
        "Prostatic Neoplasm",
        "Urogenital Neoplasms",
        "Genital Neoplasms, Male",
        "Localized Cancer"
      ],
      "interventions": [
        {
          "name": "NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NanOlogy, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2020-10-20",
      "completion_date": "2021-02-08",
      "has_results": true,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Kansas City, Kansas • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04221828"
    },
    {
      "nct_id": "NCT06847698",
      "title": "Single Ascending Dose and Multiple Ascending Dose Study of AVR-48",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety Issues",
        "Tolerability",
        "Pharmacokinetics",
        "Pharmacodynamics"
      ],
      "interventions": [
        {
          "name": "AVR-48",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AyuVis Research, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2025-06",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06847698"
    },
    {
      "nct_id": "NCT04049331",
      "title": "Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypogonadism, Male",
        "Fatigue Syndrome, Chronic"
      ],
      "interventions": [
        {
          "name": "Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seattle Institute for Biomedical and Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "MALE",
        "summary": "18 Years to 54 Years · Male only"
      },
      "enrollment_count": 240,
      "start_date": "2021-03-22",
      "completion_date": "2027-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04049331"
    },
    {
      "nct_id": "NCT04634253",
      "title": "A Study of LY3462817 in Participants With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LY3462817",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2021-01-04",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-12",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 7,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Palm Desert, California + 4 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634253"
    },
    {
      "nct_id": "NCT02788045",
      "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.Mos4.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 201,
      "start_date": "2016-07-08",
      "completion_date": "2022-04-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788045"
    },
    {
      "nct_id": "NCT00937677",
      "title": "Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Tysabri",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 85,
      "start_date": "2007-11",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2011-09-07",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00937677"
    },
    {
      "nct_id": "NCT05492851",
      "title": "Trial Comparing Three Single Dose Injections for Knee Osteoarthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Zilretta",
          "type": "DRUG"
        },
        {
          "name": "Synvisc-One 48 MG in 6 ML Prefilled Syringe",
          "type": "DRUG"
        },
        {
          "name": "Monovisc 88 MG Per 4 ML Prefilled Syringe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "25 Years to 85 Years"
      },
      "enrollment_count": 6,
      "start_date": "2022-08-02",
      "completion_date": "2023-01-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Lewis Center, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Lewis Center",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05492851"
    },
    {
      "nct_id": "NCT02697253",
      "title": "Mechanisms Underlying Predictors of Success From Obesity Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Exendin 9-39 and Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-01",
      "completion_date": "2021-07-29",
      "has_results": false,
      "last_update_posted_date": "2022-11-15",
      "last_synced_at": "2026-10-15T17:06:52.009Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02697253"
    }
  ]
}